ExoVasc® PEARS

ExoVasc® reaches 750 patient milestone

Exstent Ltd is proud to announce that at the beginning of March, 750 patients have been successfully implanted with ExoVasc® – 650 Aortic PEARS patients and 100 Ross PEARS patients. Thank you to all those involved in the PEARS projects including all PEARS surgeons and their support teams, Exstent’s employees and distributors.

A new, innovative procedure is a big step forward for patients with an enlarged aorta

Exstent Appoints Matt Thompson as CEO to Drive Global Growth in Personalised Aortic Support

Interested in our patient experiences?

We develop medical devices that manage aortic dilatation and minimise the risk of aortic dissection.

quick links

statements & policies

Our contact details

The staff of Exstent Limited are not medically qualified and are thus not able to provide clinical advice or answer questions of a clinical nature. We may direct your attention to publications in peer-reviewed journals that provide clinical information or provide information based upon personal experience. However, for any questions of a clinical nature patients are recommended to consult a qualified clinician.